DECREASED RISK FOUND AFTER MRNA VACCINE Having a COVID-19 infection is associated with an increased risk of developing the rare disorder called Guillain-Barré syndrome within the next six weeks, according to a study published in the October 18, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study also
Tens of thousands of people in England may have lasting symptoms from COVID‐19 more than a year after infection, new analysis reveals. The findings come from a representative sample of more than a quarter of a million people in England surveyed as part of the REACT study, who self-reported their symptoms and the impact of COVID-19
Clocking up just 20–25 minutes of physical activity every day may be enough to offset the heightened risk of death from a highly sedentary lifestyle, suggests research published online in the British Journal of Sports Medicine. But higher daily tallies of physical activity are linked to a lower risk, irrespective of the amount of time spent
In a study published in The New England Journal of Medicine, clinicians and researchers from the CHU of Liège and the University of Liège show that the administration of plasma taken from convalescent donors after infection with Sars-CoV-2 to patients suffering from acute respiratory distress syndrome requiring artificial mechanical ventilation significantly reduced mortality (10%). he randomised
Women, children and newborns in Gaza are disproportionately bearing the burden of the escalation of hostilities in the occupied Palestinian territory, both as casualties and in reduced access to health services, warn the United Nations Children’s Fund (UNICEF), the United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA), the United Nations
Researchers have identified 38 businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies for preventing and treating COVID-19 even though these “interventions” have not been approved or authorized by national regulatory bodies and are not supported by convincing safety and efficacy data. The analysis, appearing in the journal Stem Cell Reports, also found
Novartis presented data from the Phase III PSMAfore trial at the 2023 European Society for Medical Oncology (ESMO) Congress. Data presented at the Presidential Symposium showed that Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan) met its primary endpoint with a clinically meaningful and statistically significant benefit in radiographic progression-free survival (rPFS) in patients with prostate-specific membrane antigen
The trial, which is ongoing in the U.K. and New Zealand, has been on hold in the U.S. since late last year as the FDA sought more details from Verve. Verve Therapeutics plans to soon start testing a gene editing therapy for heart disease in the U.S. after federal regulators lifted an order that had
Researchers are testing an approach that involves replacing a mutated gene in the inner ears of children with severe hearing loss. Two companies have launched clinical trials to see if they can restore hearing to children with a rare type of genetic deafness. Akouos and Decibel Therapeutics, both based in Boston, are testing experimental therapies in
Glioblastoma (GBM), an aggressive brain cancer, is notoriously resistant to treatment, with recurrent GBM associated with survival of less than 10 months. Immunotherapies, which mobilize the body’s immune defenses against a cancer, have not been effective for GBM, in part because the tumor’s surrounding environment is largely impenetrable to assaults from the body’s immune system.
